SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.
Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285
Upon joining, please ask to be joined into the Nephros conference call.
An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Alternatively, a replay of the call may be accessed until November 14, 2024 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 5018166.
About Nephros
Nephros is a leading provider of filtration products to the medica, commercial, and industrial markets, offering a wide range of solutions that deliver superior filtration performance. With its advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality.
For more information about Nephros, please visit us at nephros.com.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
This email address is being protected from spambots. You need JavaScript enabled to view it.
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.70 |
Daily Change: | 0.07 2.66 |
Daily Volume: | 26,858 |
Market Cap: | US$28.460M |
November 07, 2024 October 24, 2024 November 08, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load